Researchers at the University of California, Berkeley have developed a new type of medical cannabis that is more effective at relieving pain and inflammation than traditional strains. The new strain, called “CB2-selective cannabis,” is designed to target the CB2 cannabinoid receptor, which is involved in pain and inflammation.

Traditional strains of cannabis typically target the CB1 cannabinoid receptor, which is responsible for the psychoactive effects of cannabis. However, the CB2 receptor is not psychoactive, so CB2-selective cannabis does not produce a high.

In a study published in the journal Pain, the researchers found that CB2-selective cannabis was more effective at relieving pain and inflammation in mice than traditional strains of cannabis. The researchers also found that CB2-selective cannabis was not associated with any negative side effects.

The researchers believe that CB2-selective cannabis could be a valuable new treatment option for people with chronic pain and inflammation. They are currently planning to conduct clinical trials of CB2-selective cannabis in humans.

If these clinical trials are successful, CB2-selective cannabis could become a new and improved way to treat chronic pain and inflammation without the psychoactive effects of traditional strains of cannabis.

Researchers at the University of California, Berkeley have developed a new type of medical cannabis that is more effective at relieving pain and inflammation than traditional strains. The new strain, called “CB2-selective cannabis,” is designed to target the CB2 cannabinoid receptor, which is involved in pain and inflammation¹.

Traditional strains of cannabis typically target the CB1 cannabinoid receptor, which is responsible for the psychoactive effects of cannabis. However, the CB2 receptor is not psychoactive, so CB2-selective cannabis does not produce a high¹.

In a study published in the journal Pain, the researchers found that CB2-selective cannabis was more effective at relieving pain and inflammation in mice than traditional strains of cannabis. The researchers also found that CB2-selective cannabis was not associated with any negative side effects¹.

The researchers believe that CB2-selective cannabis could be a valuable new treatment option for people with chronic pain and inflammation. They are currently planning to conduct clinical trials of CB2-selective cannabis in humans¹.

If these clinical trials are successful, CB2-selective cannabis could become a new and improved way to treat chronic pain and inflammation without the psychoactive effects of traditional strains of cannabis¹.

Learn more:

1. frontiersin.org2. leafly.com3. frontiersin.org4. en.wikipedia.org5. doi.org6. cell.com7. frontiersin.org